Natural Cycle Versus Hormone Replacement Therapy Cycle for a Frozen-thawed Embryo Transfer in PGT Patients

• Status: Recruiting
• Trial end date: 2022-10-01
• Target enrollment: 0
• Participant gender: Female

Summary

The aim of the current study is to compare miscarriage rates (before 8 weeks) between a true natural cycle (awaiting spontaneous LH surge) and a hormone replacement therapy cycle prior to blastocyst transfer in preimplantation genetic testing (PGT) patients, with biopsy on day 5 of embryonic development. The advantage of performing the study in PGT patients is the exclusion of aneuploidy as a cause of miscarriage.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: CRG UZ Brussel
• Treatments: Estradiol; Estradiol 17 beta-cypionate; Estradiol 3-benzoate; Follicle Stimulating Hormone; Hormones; Polyestradiol phosphate; Progesterone

Criteria

Inclusion Criteria:

• BMI under 35 kg/m2

• Regular menstrual cycle pattern (i.e. 24-35 days cycle)

• First, second and third ICSI-PGT cycle

• First frozen embryo transfer cycle following a fresh ICSI-PGT attempt

• PGT with trophectoderm biopsy on day 5 of embryonic development

• Signed informed consent

Exclusion Criteria:

• Oligo-amenorrhea

• BMI above 35

• Contraindications for the use of hormonal replacement therapy